There’s a clear divide in how we're looking at the proteomic crash of aging. On one side, we have the Ribosomal Fidelity Hypothesis. This model posits that aging is driven by the ribosome losing its ability to accurately select tRNA. We end up with a "stuttering" proteome—proteins that are 99% accurate but contain that one fatal amino acid substitution that triggers misfolding and aggregation.

On the other side sits the Splicing Entropy Hypothesis. Here, the fault lies with the editor rather than the factory worker. As we age, the spliceosome loses its precision and begins missing canonical splice sites. This results in the inclusion of "cryptic" exons, creating truncated, toxic isoforms that the cell’s quality control systems were never built to manage.

I’d bet on Splicing Entropy being the real driver of systemic aging.

Splicing is simply too energetically and topologically fragile. It relies on the U-snRNP complex performing a precise choreography within a nucleus that’s increasingly cluttered by DNA damage and collapsing chromatin boundaries. While the ribosome is fairly robust in the cytoplasm, the spliceosome is on the front lines of nuclear decay. Splicing noise shows up as an early-onset feature of senescence, usually years before we see measurable ribosomal drift.

The Ribosomal camp points to data showing that slowing translation can extend lifespan, but they’re likely just treating a symptom by reducing the volume of a corrupted signal. If we don’t maintain RNA integrity, fixing the ribosome is just polishing the brass on a sinking ship.

We need a pivot. Funding should move toward spliceosome stabilization and isoform-specific proteomics. We’re still leaning on bulk RNA-seq, which averages out the very noise that's killing us. I'm looking for collaborators who can bridge high-resolution structural biology with real-time in vivo fidelity tracking.

Are we failing because our production is sloppy, or because we can't read the blueprint anymore? I suspect it's the latter.